ArticleThe Journal of experimental medicine2006
Functional disruption of alpha4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization.
Article in The Journal of experimental medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 108 citations in OpenAlex.
- Integrin α4β7: Pathogenic Roles in Metabolic and Inflammatory Diseases and Translational Therapeutics.Journal of inflammation research · 2026Review
- The mechanisms and applications of endothelial progenitor cell therapy in the treatment of intracranial aneurysm.Journal of translational medicine · 2025Review
- Potential role of endothelial progenitor cells in the pathogenesis and treatment of cerebral aneurysm.Frontiers in cellular neuroscience · 2024Review
- Poly(l-lactic acid) Scaffold Releasing an αACS applied bio materials · 2023Article
- A small-diameter vascular graft immobilized peptides for capturing endothelial colony-forming cells.Frontiers in bioengineering and biotechnology · 2023Article
- Review
- Experimental Animal Models for Moyamoya Disease: A Species-Oriented Scoping Review.Frontiers in surgery · 2022Article
- Membrane-bound SCF and VCAM-1 synergistically regulate the morphology of hematopoietic stem cells.The Journal of cell biology · 2021Article
- Role of Stromal Cell-Derived Factor-1 in Endothelial Progenitor Cell-Mediated Vascular Repair and Regeneration.Tissue engineering and regenerative medicine · 2021Review
- Neovascularization and tissue regeneration by endothelial progenitor cells in ischemic stroke.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Review
- Transplantation of CD34+ cells for myocardial ischemia.World journal of transplantation · 2021Review
- Visualization and Identification of Bioorthogonally Labeled Exosome Proteins Following Systemic Administration in Mice.Frontiers in cell and developmental biology · 2021Article
- Analysis of mesenchymal stem cell proteomesTheranostics · 2020Article
- Sam68 impedes the recovery of arterial injury by augmenting inflammatory response.Journal of molecular and cellular cardiology · 2019Article
- Role of CXCR2 in the Ac-PGP-Induced Mobilization of Circulating Angiogenic Cells and its Therapeutic Implications.Stem cells translational medicine · 2019Article
- E2F1 Suppresses Oxidative Metabolism and Endothelial Differentiation of Bone Marrow Progenitor Cells.Circulation research · 2018Article
- Murine Double Minute-2 Inhibition Attenuates Cardiac Dysfunction and Fibrosis by Modulating NF-κB Pathway After Experimental Myocardial Infarction.Inflammation · 2017Article
- Stem Cell-Derived Exosomes, Autophagy, Extracellular Matrix Turnover, and miRNAs in Cardiac Regeneration during Stem Cell Therapy.Stem cell reviews and reports · 2017Review
- Endothelial Progenitor Cells for Ischemic Stroke: Update on Basic Research and Application.Stem cells international · 2017Review
- Enhanced Integrin α4β1-Mediated Adhesion Contributes to a Mobilization Defect of Endothelial Progenitor Cells in Diabetes.Diabetes · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 2 countries.
Funding
Abstract
The cell surface receptor alpha4 integrin plays a critical role in the homing, engraftment, and maintenance of hematopoietic progenitor cells (HPCs) in the bone marrow (BM). Down-regulation or functional blockade of alpha4 integrin or its ligand vascular cell adhesion molecule-1 mobilizes long-term HPCs. We investigated the role of alpha4 integrin in the mobilization and homing of BM endothelial progenitor cells (EPCs). EPCs with endothelial colony-forming activity in the BM are exclusively alpha4 integrin-expressing cells. In vivo, a single dose of anti-alpha4 integrin antibody resulted in increased circulating EPC counts for 3 d. In hindlimb ischemia and myocardial infarction, systemically administered anti-alpha4 integrin antibody increased recruitment and incorporation of BM EPCs in newly formed vasculature and improved functional blood flow recovery and tissue preservation. Interestingly, BM EPCs that had been preblocked with anti-alpha4 integrin ex vivo or collected from alpha4 integrin-deficient mice incorporated as well as control cells into the neovasculature in ischemic sites, suggesting that alpha4 integrin may be dispensable or play a redundant role in EPC homing to ischemic tissue. These data indicate that functional disruption of alpha4 integrin may represent a potential angiogenic therapy for ischemic disease by increasing the available circulating supply of EPCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.